Trial Profile
Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 17 May 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Dec 2024.
- 14 May 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Apr 2022.
- 10 Jul 2020 Status changed from active, no longer recruiting to recruiting.